An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial

An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial

Abstract Background This study focuses on genetically stratified subgroups of Parkinson’s disease patients (PD) with an enrichment of risk variants in mitochondrial genes,who might benefit from treatment with the “mitochondrial enhancer” coenzyme Q10 (156 mg coenzyme Q10/d [QuinoMit Q10® Fluid] over...

Full description

Bibliographic Details
Main Authors: Jannik Prasuhn, Norbert Brüggemann, Nicole Hessler, Daniela Berg, Thomas Gasser, Kathrin Brockmann, Denise Olbrich, Andreas Ziegler, Inke R. König, Christine Klein, Meike Kasten
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Neurological Research and Practice
Subjects:
Parkinson’s disease
Coenzyme Q10
Personalized medicine
PINK1
Parkin
Mitochondrial dysfunction
Online Access:http://link.springer.com/article/10.1186/s42466-019-0033-1

Internet

http://link.springer.com/article/10.1186/s42466-019-0033-1

Similar Items